187 related articles for article (PubMed ID: 12480313)
1. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur.
Zhang L; Parsons DL; Navarre C; Kompella UB
J Control Release; 2002 Dec; 85(1-3):73-81. PubMed ID: 12480313
[TBL] [Abstract][Full Text] [Related]
2. Sustained release of lidocaine from Poloxamer 407 gels.
Ricci EJ; Lunardi LO; Nanclares DM; Marchetti JM
Int J Pharm; 2005 Jan; 288(2):235-44. PubMed ID: 15620863
[TBL] [Abstract][Full Text] [Related]
3.
Hemelryck SV; Dewulf J; Niekus H; van Heerden M; Ingelse B; Holm R; Mannaert E; Langguth P
Int J Pharm X; 2019 Dec; 1():100016. PubMed ID: 31517281
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.
Bhardwaj R; Blanchard J
J Pharm Sci; 1996 Sep; 85(9):915-9. PubMed ID: 8877878
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide.
Erfani Jabarian L; Rouini MR; Atyabi F; Foroumadi A; Nassiri SM; Dinarvand R
Eur J Pharm Sci; 2013 Jan; 48(1-2):87-96. PubMed ID: 23131800
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of an in situ forming gel system for sustained delivery of Florfenicol.
Yu ZG; Geng ZX; Liu TF; Jiang F
J Vet Pharmacol Ther; 2015 Jun; 38(3):271-7. PubMed ID: 25287575
[TBL] [Abstract][Full Text] [Related]
7. Development and characterisation of modified poloxamer 407 thermoresponsive depot systems containing cubosomes.
Kojarunchitt T; Hook S; Rizwan S; Rades T; Baldursdottir S
Int J Pharm; 2011 Apr; 408(1-2):20-6. PubMed ID: 21272624
[TBL] [Abstract][Full Text] [Related]
8. Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems.
Kojarunchitt T; Baldursdottir S; Dong YD; Boyd BJ; Rades T; Hook S
Eur J Pharm Biopharm; 2015 Jan; 89():74-81. PubMed ID: 25481034
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of a formulation of butorphanol tartrate in a poloxamer 407 base intended for use as a parenterally administered slow-release analgesic agent.
Laniesse D; Smith DA; Knych HK; Mosley C; Guzman DS; Beaufrère H
Am J Vet Res; 2017 Jun; 78(6):677-687. PubMed ID: 28541144
[TBL] [Abstract][Full Text] [Related]
10. The clinical efficacy of cosmeceutical application of liquid crystalline nanostructured dispersions of alpha lipoic acid as anti-wrinkle.
Sherif S; Bendas ER; Badawy S
Eur J Pharm Biopharm; 2014 Feb; 86(2):251-9. PubMed ID: 24056055
[TBL] [Abstract][Full Text] [Related]
11. Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels.
Mansour M; Mansour S; Mortada ND; Abd Elhady SS
Drug Dev Ind Pharm; 2008 Jul; 34(7):744-52. PubMed ID: 18612913
[TBL] [Abstract][Full Text] [Related]
12. Preformulation and characterization of a lidocaine hydrochloride and dexamethasone sodium phosphate thermo-reversible and bioadhesive long-acting gel for intraperitoneal administration.
Arbelaez-Camargo D; Suñé-Negre JM; Roig-Carreras M; García-Montoya E; Pérez-Lozano P; Miñarro-Carmona M; Ticó-Grau JR
Int J Pharm; 2016 Feb; 498(1-2):142-52. PubMed ID: 26685726
[TBL] [Abstract][Full Text] [Related]
13. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity.
Jones DS; Bruschi ML; de Freitas O; Gremião MP; Lara EH; Andrews GP
Int J Pharm; 2009 May; 372(1-2):49-58. PubMed ID: 19429268
[TBL] [Abstract][Full Text] [Related]
14. Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer.
Ochoa L; Igartua M; Hernández RM; Gascón AR; Pedraz JL
J Pharm Pharm Sci; 2005 Jun; 8(2):132-40. PubMed ID: 16124924
[TBL] [Abstract][Full Text] [Related]
15. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.
M A Fathalla Z; Vangala A; Longman M; Khaled KA; Hussein AK; El-Garhy OH; Alany RG
Eur J Pharm Biopharm; 2017 May; 114():119-134. PubMed ID: 28126392
[TBL] [Abstract][Full Text] [Related]
16. Poloxamer 407 based-nanoparticles for controlled release of methotrexate.
Moura S; Noro J; Cerqueira P; Silva C; Cavaco-Paulo A; Loureiro A
Int J Pharm; 2020 Feb; 575():118924. PubMed ID: 31870962
[TBL] [Abstract][Full Text] [Related]
17. Cyclodextrin-poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B.
Jansook P; Pichayakorn W; Muankaew C; Loftsson T
Drug Dev Ind Pharm; 2016 Sep; 42(9):1446-54. PubMed ID: 26765786
[TBL] [Abstract][Full Text] [Related]
18. A Novel Thermoresponsive Gel as a Potential Delivery System for Lipoxin.
Wang B; Shao J; Jansen JA; Walboomers XF; Yang F
J Dent Res; 2019 Mar; 98(3):355-362. PubMed ID: 30403904
[TBL] [Abstract][Full Text] [Related]
19. Poloxamer-based in situ hydrogels for controlled delivery of hydrophilic macromolecules after intramuscular injection in rats.
Zhang K; Shi X; Lin X; Yao C; Shen L; Feng Y
Drug Deliv; 2015 May; 22(3):375-82. PubMed ID: 24601854
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion.
De Brabander C; Vervaet C; Remon JP
J Control Release; 2003 Apr; 89(2):235-47. PubMed ID: 12711447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
